Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sagartz, J. E.
Right arrow Articles by Alden, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sagartz, J. E.
Right arrow Articles by Alden, C. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal Article

Phenobarbital Does Not Promote Hepatic Tumorigenesis in a Twenty-Six-Week Bioassay in p53 Heterozygous Mice

John E. Sagartz

Product Safety Assessment, Searle, St. Louis, Missouri 63167

Sandra W. Curtiss

Product Safety Assessment, Searle, St. Louis, Missouri 63167

Roderick T. Bunch

Product Safety Assessment, Searle, St. Louis, Missouri 63167

Julio C. Davila

Product Safety Assessment, Searle, St. Louis, Missouri 63167

Dale L. Morris

Product Safety Assessment, Searle, St. Louis, Missouri 63167

Carl L. Alden

Product Safety Assessment, Searle, St. Louis, Missouri 63167

The tumorigenic potential of phenobarbital was examined in a 26-wk carcinogenesis bioassay using p53 heterozygous mice and wild-type controls. Fifteen mice/sex/genotype were exposed to either 500 or 1,000 ppm phenobarbital in the diet. Dietary administration of 3,750 ppm p-cresidine, a transspecies mutagenic carcinogen, to both heterozygous and wild-type mice served as a positive control. Phenobarbital treatment caused increases in liver: body weight ratios and histologic evidence of centrilobular hepatocellular hypertrophy. No tumors were observed in any phenobarbital-treated mice. Mice given p-cresidine exhibited a moderate reduction in body weight gain over the couise of the study. Heterozygous mice treated with p-cresidine exhibited a high incidence of urinary bladder tumors. Similar tumors were also present in a small number of p-cresidine-treated wild-type mice. Our results demonstrate the lack of a hepatic tumor response to phenobarbital, a compound that is a potent and prototypic hepatic microsomal enzyme inducer, a nongenotoxic rodent carcinogen, and a human noncarcinogen. This finding supports the continued utility of this model as an alternative to the mouse bioassay for human carcinogenic safety assessment of potentially genotoxic carcinogens because it did not produce a false-positive response to this potent nongenotoxic agent.

Key Words: p-Cresidine • urinary bladder • liver • carcinogenesis • bioassay • neoplasia

Toxicologic Pathology, Vol. 26, No. 4, 492-500 (1998)
DOI: 10.1177/019262339802600405


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Toxicol PatholHome page
D. Morton, K. L. Bailey, C. L. Stout, R. J. Weaver, K. A. White, M. J. Lorenzen, and D. J. Ball
N-Methyl-N-Nitrosourea (MNU): A Positive Control Chemical for p53+/- Mouse Carcinogenicity Studies
Toxicol Pathol, December 1, 2008; 36(7): 926 - 931.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
E. Floyd, P. Mann, G. Long, and R. Ochoa
The Trp53 Hemizygous Mouse in Pharmaceutical Development: Points to Consider for Pathologists
Toxicol Pathol, January 1, 2002; 30(1): 147 - 156.
[Abstract] [PDF]


Home page
Toxicol PatholHome page
R. D. Storer, J. E. French, J. Haseman, G. Hajian, E. K. Legrand, G. G. Long, L. A. Mixson, R. Ochoa, J. E. Sagartz, and K. A. Soper
p53 +/- Hemizygous Knockout Mouse: Overview of Available Data
Toxicol Pathol, January 1, 2001; 29(1_suppl): 30 - 50.
[Abstract] [PDF]


Home page
International Journal of ToxicologyHome page
A. P. Brown, R. L. Morrissey, T. A. Tolhurst, J. A. Crowell, and B. S. Levine
Oral Toxicity of 1,2-Dithiole-3-Thione, a Potential Cancer Chemopreventive Agent, in the Rat
International Journal of Toxicology, November 1, 2000; 19(6): 375 - 381.
[Abstract] [PDF]


Home page
Toxicol SciHome page
D. A. Delker, B. L. Yano, and B. B. Gollapudi
Evaluation of Cytotoxicity, Cell Proliferation, and Genotoxicity Induced by p-Cresidine in Hetero- and Nullizygous Transgenic p53 Mice
Toxicol. Sci., June 1, 2000; 55(2): 361 - 369.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
D. Gulezian, D. Jacobson-Kram, C. B. Mccullough, H. Olson, L. Recio, D. Robinson, R. Storer, R. Tennant, J. M. Ward, and D. A. Neumann
Review Article: Use of Transgenic Animals for Carcinogenicity Testing: Considerations and Implications for Risk Assessment
Toxicol Pathol, May 1, 2000; 28(3): 482 - 499.
[Abstract] [PDF]


Home page
Toxicol PatholHome page
R. R. Maronpot
The Potential of Genetically Altered Mice as Animal Models for Carcinogen Identification
Toxicol Pathol, July 1, 1998; 26(4): 579 - 581.
[PDF]